[PRESS RELEASE] – PANAMA CITY, July 9, 2026 – Tilray Medical, a division of Tilray Brands Inc. and a leading global medical cannabis company, announced the commercial launch of its first medical cannabis product in Panama, marking a significant milestone in the company’s ongoing global expansion and commitment to improving patient access to pharmaceutical-grade cannabinoid medicines worldwide.
The launch follows the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP-certified production facilities in Portugal through its joint venture with Solana Life Group S. de R.L.
The product is intended to be distributed through Farmacias Arrocha, one of Panama’s leading pharmacy networks, where patients will be able to access Tilray Oral Solution CBD100 under medical prescription. This is expected to provide patients and health care professionals with access to regulated, pharmaceutical-quality medical cannabis through established health care channels.
The milestone reinforces Tilray Medical’s position as one of the most geographically diversified medical cannabis companies globally. Today, Tilray Medical serves patients across more than 20 countries spanning Europe, Australia, Canada, Latin America and other emerging international markets, helping advance access to safe, high-quality cannabinoid-based medicines through regulated health care systems.
Rajnish Ohri, president of international at Tilray Brands, said, “At Tilray Medical, we believe every patient deserves access to safe, consistent, pharmaceutical-grade medical cannabis products. Our commercial launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines through trusted health care systems around the world. As medical cannabis frameworks continue to advance, we are committed to working alongside health care providers, regulators, pharmacists and patients to help shape the future of responsible access, advance medical education, and deliver high-quality treatment options that improve lives.”
The launch supports Panama’s emerging medical cannabis framework established under Law 242 of 2021 and follows important regulatory advancements by the Ministry of Health, including Resolution No. 0406 of May 12, 2026, which established key requirements for patient access. The Ministry also recently introduced the Medical Cannabis Users and Authorized Caregivers Identification System (SIUCMAA), creating a structured pathway for physician authorization and patient registration.
Manufactured in Portugal in accordance with rigorous European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use, where authorized, in patients with qualifying medical conditions authorized under Panamanian legislation. The product reflects Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.
Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP-certified medical cannabis products to regulated markets around the world. The platform enables Tilray Medical to efficiently support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.
The Panama launch represents another step in Tilray Medical’s broader strategy to expand access across Latin America, an emerging medical cannabis region. As governments across the region continue to establish regulatory pathways for cannabinoid-based medicines, Tilray Medical is well-positioned to support health care systems with trusted products, scientific expertise and a proven track record of operating in highly regulated international markets.
As global acceptance of medical cannabis continues to accelerate, Tilray Medical remains focused on advancing patient care, supporting clinical education, investing in research and expanding access to high-quality medical cannabis products that help address unmet patient needs worldwide.
For further information, visit: www.Solana.pa
